Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 6Completed 5Withdrawn 3Terminated 3Recruiting 3Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 2Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 9Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Solid Tumor, Adult 1Recurrence 1Rectal Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neutropenia 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Cystadenocarcinoma, Serous 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × niraparib × Clear all
NCT05169437 2025-10-29

PAVO

Tempus AI

Phase 2 Terminated
22 enrolled 17 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT01905592 2022-11-15

BRAVO

Tesaro, Inc.

Phase 3 Terminated
216 enrolled 19 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02826512 2022-07-18

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

The Netherlands Cancer Institute

Phase 2 Terminated
9 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡